Treatment of paradoxical eczematous eruption in psoriasis treated with secukinumab: A case report

Article Dermatology

Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?

Matteo Megna et al.

Summary: This study described the clinical and histological features of Eczematous drug eruption (EDE) induced by anti-IL-17A biologics, as well as the skin cytokine milieu. The findings suggest that EDE lesions have predominantly Th2/Th22 features, with IL-22 playing a major role in their pathogenesis.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis

Eduardo Mendes Roncada et al.

Summary: Secukinumab and ustekinumab are effective and safe treatments for moderate to severe psoriasis, with rare side effects and the possibility of paradoxical reactions like atopic dermatitis.

CASE REPORTS IN DERMATOLOGY (2021)

Add to Collection

Review Dermatology

Eczematous Drug Eruptions

Amy E. Blum et al.

Summary: Eczematous drug eruptions are a diverse group of skin reactions caused by various pathophysiologic etiologies, with treatments typically involving emollients, topical corticosteroids, and oral antihistamines.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal